Latham & Watkins Represents Placement Agents in PIPE in Connection With Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation’s Proposed Business Combination

Memic Innovative Surgery Ltd., a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, and MedTech Acquisition Corporation, a publicly traded special purpose acquisition company (SPAC) focused on medical technology, including surgical robotics, have announced that they have entered into a definitive agreement for a business combination. Upon the closing of the transaction, the combined company will operate under the Memic name and Maurice R. Ferré, MD, an independent director of MedTech and current Chairman of the board of Memic, will become Executive Chairman of the combined company. Memic will apply to have its ordinary shares listed on The Nasdaq Stock Market. The business combination is supported by a US$76 million PIPE with participation from leading investors, including Bridger Healthcare, Ltd., The Kraft Group, Monashee Investment Management LLC, Pura Vida Investments, Wellington Management, Ken Langone, Peregrine Ventures, HighSage Ventures, and management and board members of MedTech. The business combination is expected to be completed in the fourth quarter of 2021.

Latham & Watkins LLP represented the placement agents in the PIPE with a capital markets team led by partner Nathan Ajiashvili and counsel Michael Rosenberg.